Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Resistant high blood pressure

Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Resistant hypertension means blood pressure above target despite three medicines from different classes, one of them a diuretic, at proper doses.

Before that label is accepted, three things account for most of it: the readings are not accurate, the tablets are not being taken, or something is being taken that raises pressure.

Related pages: High blood pressure (hypertension)

The bottom line

What we know
  • Resistant hypertension is defined as uncontrolled pressure on three drugs including a diuretic.
  • Much apparent resistance is pseudoresistance from measurement, adherence or interfering substances.
  • Spironolactone was the most effective fourth drug in a randomized comparison.
  • Primary aldosteronism and sleep apnoea are both common in resistant hypertension.
What is still open
  • How much renal denervation contributes in routine practice, which is still being established.
  • The best fourth-line option for people who cannot take spironolactone.

The story, step by step

  1. 1. Pseudoresistance ()
  2. 2. True resistance ()
  3. 3. Devices and what is next ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 3

What to rule out first

Review of many studies

What happens

The three explanations that cover most cases.

What the research shows

  • Measurement. An undersized cuff, an unsupported arm, no rest beforehand, or white-coat effect can each produce apparent resistance. Out-of-office monitoring is the way to settle it, and a proportion of resistant hypertension disappears on 24-hour monitoring.
  • Adherence. Studies using urine or blood drug-level testing find that a large share of people with apparently resistant hypertension are not taking some or all of their medicines. This is not a moral failing: side effects, cost, complexity and simply forgetting all contribute, and it is far more productive to ask about than to assume.
  • Interfering substances. NSAIDs are the commonest, followed by decongestants, steroids, stimulants, oral contraceptives, excess alcohol and liquorice.
  • Suboptimal regimen. A diuretic at too low a dose, hydrochlorothiazide where a longer-acting thiazide-like drug would do better, or three drugs that overlap in mechanism.
  • Excess sodium intake, which blunts nearly every antihypertensive and is rarely measured. A 24-hour urine sodium shows what is actually being eaten.
  • Each of these is addressable, and together they explain most apparent resistance.

Why it matters

Being asked directly whether you are taking the tablets is not an accusation; it is the most useful question in the consultation and the hardest to ask well.

What's still uncertain

  • What proportion of resistant hypertension is non-adherence, where estimates vary widely by method.

Read more

Next: True resistance

Part 2 of 3

What is done next

Review of many studies

What happens

The fourth drug, and the search for a cause.

What the research shows

  • The PATHWAY-2 trial compared spironolactone, bisoprolol, doxazosin and placebo as a fourth drug in resistant hypertension. Spironolactone was clearly the most effective.
  • That result also points at the mechanism: much resistant hypertension involves excess sodium retention driven by aldosterone, whether or not formal primary aldosteronism is present.
  • Spironolactone requires monitoring of potassium and kidney function, is used cautiously in reduced kidney function, and can cause breast tenderness in men, in which case eplerenone or amiloride may be used.
  • Screening for primary aldosteronism belongs here, and is frequently skipped. The aldosterone-to-renin ratio is a blood test, and the yield in resistant hypertension is high.
  • Screening for obstructive sleep apnoea belongs here too, for the same reason.
  • Optimizing the diuretic matters: switching to chlorthalidone or indapamide, or to a loop diuretic where kidney function is reduced.
  • Specialist referral is appropriate at this point, and people are often referred years later than they should be.

Why it matters

Spironolactone plus screening for aldosteronism and sleep apnoea is the core of modern management, and all three are underused.

What's still uncertain

  • Who benefits most from spironolactone, which plasma renin may help predict.

Read more

Next: Devices and what is next

Part 3 of 3

Renal denervation and beyond

Review of many studies

What happens

Where procedures now stand.

What the research shows

  • Renal denervation uses a catheter to interrupt sympathetic nerves running along the renal arteries. Early uncontrolled studies were enthusiastic, a sham-controlled trial then found no benefit, and the field reworked both the technique and the trial design.
  • Subsequent properly blinded trials have shown modest but real blood pressure reductions, and devices received FDA approval in the United States in late 2023.
  • It is an option for selected people with uncontrolled hypertension despite treatment, or who cannot tolerate medicines, rather than a replacement for them.
  • The effect size is roughly comparable to adding one medicine, which is useful rather than transformative, and long-term durability is still being established.
  • Other device approaches, including baroreceptor stimulation and arteriovenous coupling, remain investigational.
  • New drug classes are in development, including aldosterone synthase inhibitors and agents targeting angiotensinogen with dosing intervals measured in months, which could change the adherence problem fundamentally.
  • Clinical trials are a reasonable thing to ask about for anyone whose pressure remains uncontrolled on maximal treatment.

Why it matters

The honest summary on denervation is a real but modest effect, available for people who have run out of other options, and not a cure.

What's still uncertain

  • Long-term durability and the best patient selection for renal denervation.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.